US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition
Time:2024-05-21 19:22:48 Source:healthViews(143)
WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Previous:Elon Musk gets approval from FDA to implant his Neuralink brain chip into a second patient
Next:Philippines blames China for loss of giant clams in disputed shoal and urges environmental inquiry
You may also like
- Uber and Lyft say they'll stay in Minnesota after Legislature passes driver pay compromise
- Robin Goodfellow's racing tips: Best bets for Saturday, May 18
- Beijing parks present 109 cultural events for Spring Festival holiday
- Katie Holmes exudes boho chic as she layers up in a loose
- Red Lobster seeks bankruptcy protection after closing some restaurants
- John Stamos shares rare photo with BOTH Mary
- Barcelona extend Cubarsí contract to 2027
- Mariners get fine start from Luis Castillo, use late charge to rally past Orioles 4
- Kosovo prepares a new draft law on renting prison cells to Denmark after the first proposal failed